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Chronic severe heart failure is frequently associated with disturbances in the central
control of breathing. During wakefulness, central breathing disorders could be ameliorated
with beta-blocker treatment, but nothing is known about the effects of beta-blockers on
the control of breathing during sleep. This study intends to determinate the prevalence
and severity of nocturnal apnoeas and hypopnoeas in heart failure patients treated with or
without metoprolol or carvedilol.
Fifty consecutive patients with dilated cardiomyopathy in NYHA class II–IV with a left
ventricular ejection fraction (LVEF) of 35% or below were studied with full polysomno-
graphy over one night.
The mean Apnoea–Hypopnoea Index of beta-blocker free patients was 19.8714.2 versus
7.478.5 (po0.05) and 8.778.1 (po0.05) in patients treated with metoprolol or
carvedilol, respectively. The arousal index, sleep quality, and daytime sleepiness were
improved in similar magnitude.
Conclusion: Long-term treatment of patients with advanced chronic heart failure with
sufficient doses of metoprolol or carvedilol is associated with a lower prevalence and
severity of central sleep apnoea (CSA).
& 2006 Published by Elsevier Ltd.Published by Elsevier Ltd.
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About 20–40% of patients with advanced chronic heart
failure suffer from central breathing disorders.1 It had been
suggested that heart failure might be causally related with
alterations in the central control of breathing, resulting in
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Table 1 Anthropometric, functional and polysomno-
graphic data from 45 patients with advanced dilated
Sleep apnoea and beta-blocker treatment 851periodic breathing during the day and/or Cheyne–Stokes
respiration during sleep.2 Disorders in the central control of
breathing may be a powerful, independent predictor for
premature dying.3,4
During wakefulness, periodic breathing may appear
spontaneously, or might be provoked by exercise.5 During
sleep, the typical pattern of Cheyne–Stokes respiration can
be detected during light sleep stages, and is referred to as
central sleep apnoea (CSA).6
Long-term treatment with beta receptor blocking sub-
stances (beta-blockers) reduces the inappropriate increase
of ventilation during exercise and alleviates the central
breathing disorders during wakefulness.7,8 This resulted in
improved exercise capacity and slower progression of the
underlying heart disease.9 Until today nothing is known
about the effects of beta-blocker treatment on sleep-
related central breathing disorders.
We hypothesized that long-term application of beta-
blockers in patients with advanced dilated cardiomyopathy
influences nocturnal central breathing disorders, thereby
improving CSA.cardiomyopathy without (reference group) or with long-
term beta-blocker treatment (metoprolol or carvedilol).
Reference
group
(n ¼ 16)
All patients
on long-term
beta-blocker
treatment
(n ¼ 29)
Age (years) 58.1710.2 53.8710.5
Aetiology of dilated
cardiomyopathy ischaemic/
idiopathic/unknown, n
12/4/0 18/9/2
NYHA functional class II/III/
IV, n
7/7/2 13/13/3
Left ventricular ejection
fraction (%)
25.978.1 26.177.9
Epworth sleepiness score 1174 774
Apnoea–hypopnoea index 19.8714.2 8.078.2*
Arousal index 22.4713.8 9.577.5**
Sleep period time (SPT)
(min)
328.4746.1 332.7753.7
Total sleep time (TST) (min) 236.3761.5 283.0768.5
Wake (% SPT) 28.8712.0 15.9711.6**
Sleep stage 1 (% SPT) 18.379.5 15.2710.6
Sleep stage 2 (% SPT) 32.1715.0 33.079.6
Sleep stage 3 (% SPT) 6.674.6 10.676.3
Sleep stage 4 (% SPT) 9.076.3 12.478.6
Rapid eye movement (REM)
(% SPT)
5.374.2 13.076.2**
Mean SaO2 during TST (%) 93.872.2 95.071.6
SaO2o90% (% SPT) 10.6717.6 2.275.2*
Periodic limb movement
index
1.871.2 2.070.9
Data represent mean7standard deviation (SD). Beta-blocker
treatment is associated with a significantly reduced fre-
quency of apnoeas and hypopnoeas during sleep, improved
sleep time, improved sleep quality, and better oxygenation.
Statistical significant differences between the treatment
groups and the reference group are indicated with asterisks
(* po0.05; **po0.01). NYHA ¼ New York Heart Association.Patients and methods
Stable chronic heart failure patients with dilated cardio-
myopathy in NYHA class II–IV with a left ventricular ejection
fraction (LVEF) of 35% or below, were studied. ‘Stable’ was
defined as no requirement for changes in the cardiac
medication, including diuretics, within a 6 months period
prior to polysomnography. Patients with or without beta-
blocker treatment were considered. The remaining medica-
tion had to be in accordance with the Guidelines of the
European Society of Cardiology.10
Patients with uncertain compliance, obstructive sleep
apnoea (more than 5 obstructive apnoeas per hour of sleep),
restless legs syndrome or periodic limb movement syn-
drome, insomnia, co-medication with sedative effects,
implanted cardiac pacemaker, previous stroke, cardiac
valvular defects, uncontrolled diabetes, or other concomi-
tant disease with possible influence on the control of
breathing were not included. Patients with contraindica-
tions for beta-blockers (chronic obstructive pulmonary
disease, moderate or severe peripheral arterial insufficiency
in Fontaine Stage II–IV) were excluded to prevent an
overrepresentation of these patients in the control group.
The patients’ medical regimen in the previous 6 months
was taken from the complete clinical notes. The compliance
to the medical treatment had to be confirmed by each
patient. At study entry, daytime sleepiness was assessed
with the Epworth sleepiness scale,11 and polysomnography
was performed over one night.
LVEF was determined by ventriculography during cardiac
catheterization and was recently confirmed by echocardio-
graphy.
Full polysomnography was performed and scored in
accordance with international standards 12–14 by the same
person who was blinded for the medication of the patients.
The diagnosis CSA was established when at least 90% of all
detected respiratory events were of central origin.
The criterion for the diagnosis and the severity of the
sleep apnoea was the apnoea hypopnoea index (AHI), whichwas a continuous variable and the primary outcome
parameter. The statistical analysis was performed with
ANOVA and the Kruskal–Wallis Test, if appropriate. Post
hoc analysis applied the Dunnett-t-test (SPSS-software
Version 13.0, SPSS Inc., Chicago, IL, USA). A po0.05 was
considered significant.
This study was approved by the local ethics committee.
Patients gave their written informed consent prior to
inclusion into the study.
Results
Within a period of 14 months, 185 consecutive cases were
screened. Fifty patients fulfilled all in- and exclusion criteria
and agreed to participate in this study. In 5 patients,
previously undetected obstructive sleep apnoea was found,
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remaining 45 patients (38 male, 7 female) suffered from
ischaemic, idiopathic, or undetermined dilated cardiomyo-
pathy (n ¼ 30, 13, and 2 patients, respectively). Anthropo-
metric data and further details are shown in Table 1 and in
the Online supplement.
Sixteen patients were without beta-blocker treatment
since more than 6 months (reference group). Previous beta-
blocker treatment was terminated due to symptomatic
bradycardia, fatigue or impotence in 14 patients. In two
cases the reasons were unclear. The remaining 29 patients
were on regular and sufficient doses of metoprolol (n ¼ 16),
or carvedilol (n ¼ 13). Eighteen out of 45 patients (40%) had
CSA with an AHIX15.
In the reference group, CSA was found in 11 patients
(69%). In this group, the mean AHI was 19.8714.2, the mean
arousal-index was 22.4713.8, and the mean Epworth
sleepiness score was 1174.
In patients with beta-blocker treatment, CSA was
established in 7 out of 29 patients (24.1%; po0.05). The
overall AHI was 8.078.2 (po0.05), the arousal-index was
9.577.5 (po0.01), and the mean Epworth sleepiness score
was 774 (po0.05).
Subgroup analyses revealed no significant differences
between patients treated with metoprolol or carvedilol
(Online supplement).Discussion
Our data show that patients with moderate to severe dilated
cardiomyopathy have a high prevalence of CSA. Sub-dividing
of the patients into those with or without continuous beta-
blocker treatment revealed that the prevalence and
severity of CSA was significantly lower in patients with
long-term treatment with carvedilol or metoprolol.
This is the first study investigating the relation between
beta-blocker treatment and the prevalence of CSA in
chronic heart failure patients. Our patients represent a
homogeneous group with nearly pure CSA. The overall
prevalence of 40% CSA is in accordance with previously
published data.1
The differences in the severity of CSA between beta-
blocker treated and non-treated patients was of similar
magnitude like the improvements with high dose application
of oxygen 15 or continuous positive airway pressure (CPAP),16
the most widespread therapy in CSA. Limited data is
available for the effects of assisted pressure controlled
ventilation,17 acetazolamide,18 and cardiac resynchroniza-
tion therapy.19
The lower Epworth sleepiness scores in patients with long-
term beta-blocker treatment are clinically important. They
might be explained by improvements in the frequency of
arousals and the percentage and duration of uninterrupted
periods of the refreshing sleep stages (Table 1).
The physiologic effects of beta-blocker treatment and the
influence on the prognosis of chronic heart failure patients
need to be assessed in further clinical trials. Our data justify
a prospective, controlled, double blind study without the
limitations of a retrospective design. Due to the complete
absence of historical data, the current authors failed to
obtain Ethical approval for a prospective study, which needsto allocate chronic heart failure patients into a beta-
blocker-free control group.
In conclusion, this epidemiologic study demonstrates that
patients with moderate to severe dilated cardiomyopathy,
treated with sufficient doses of the beta-blockers metopro-
lol or carvedilol, had significantly lower prevalence and
severity of CSA. This was associated with better sleep
quality and reduced daytime sleepiness.
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